Navigation Links
Addrenex Pharmaceuticals Announces Licensing Agreement With Dream Pharma
Date:8/5/2009

RESEARCH TRIANGLE PARK, N.C., Aug. 5 /PRNewswire/ -- Addrenex Pharmaceuticals, a specialty pharmaceutical company dedicated to developing treatments to regulate the adrenergic system, announced today an exclusive partnership with Dream Pharma. In keeping with its long-range plan to advance the treatment of adrenergic-related conditions throughout the world, Addrenex has licensed the right to manufacture, market and sell its lead product, Clonicel, in Korea to Dream Pharma. Dream Pharma is a Division of the Hanwha Group, one of the top 10 business conglomerates in Korea.

Clonicel is being developed for both the treatment of hypertension and attention deficit hyperactivity disorder. Clonicel is a patented extended-release formulation of clonidine hydrochloride, a drug currently approved for hypertension.

"We are very excited to partner with Dream Pharma to bring this important treatment to children struggling with ADHD in Korea," said Steve Butts, Vice President, Commercial Operations at Addrenex Pharmaceuticals. "This agreement is another important milestone for Addrenex as we continue to expand our business activities globally."

This partnership agreement coincides with the 3rd anniversary of the founding of Addrenex. In just three short years, the company has signed several licensing deals with major pharmaceutical companies, advanced four products to various stages of clinical trials and acquired an extensive pipeline of compounds primed for future development. Moving forward, the company will continue to focus on developing treatments for the origin of a wide range of conditions regulated by the adrenergic system. These conditions range from menopausal flushing to insomnia to pain. Currently, these conditions are being managed symptomatically rather than addressing the root cause.

"It is exciting to see so much progress in such a short period of ti
'/>"/>

SOURCE Addrenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
2. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
3. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
4. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
5. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
6. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
8. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
9. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
10. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
11. Class Settlement Could Result in Considerable Savings for Certain Consumers of Prescription Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2015)... CT (PRWEB) , ... August 01, 2015 , ... ... Point Partners I, L.P. (“GPP”) portfolio company has acquired Premier Physical Therapy & ... it into its portfolio of state-of-the-art clinics. , “Our acquisition of Premier Physical ...
(Date:8/1/2015)... ... August 01, 2015 , ... Lume Wellness creators Alex, Robert, and Sam ... on the Apple AppStore. , The app is designed to track various metrics ... a tool to view personal health and use this information for positive behavior modification. ...
(Date:8/1/2015)... ... August 01, 2015 , ... “ reTXT ” was featured ... latest and coolest applications on the market for iOS, Android, and Windows. Joe Toohey, ... viewers allows users to clarify, edit and delete any message including ones already sent. ...
(Date:7/31/2015)... ... 31, 2015 , ... That’s right, the STASH awards have ... The Significant Technological Achievements in Secretive Horticulture (or STASH) Awards, featured in High ... that have stood the test of time. These include lighting products, organic and ...
(Date:7/31/2015)... ... July 31, 2015 , ... When the weather turned hot ... their new type of sod called Leisure Time(TM) zoysia . It's nicknamed LTZ(TM) ... To commemorate introduction of this new type of sod, Super-Sod is giving away red ...
Breaking Medicine News(10 mins):Health News:Professional Physical Therapy Now Largest Outpatient Physical Therapy Provider in Northeast With Acquisition of Premier Physical Therapy & Wellness 2Health News:Lume Wellness Launches Health and Fitness Tracker iPhone App 2Health News:Correct Auto-Correct and Clarify the Unclear with reTXT Messaging App 2Health News:The High Times S.T.A.S.H. Awards Are in, Guess Who Took Home the Prize for “Best Grow System” 2Health News:Super-Sod Introduces Leisure Time(TM) Zoysia Grass with an Adirondack Chair Promotion 2
... in adults, revs up calorie-burning, experts say , , WEDNESDAY, April ... -- the brown fat revolution, that is. , ... verified that adult humans do possess this "good," slimming form ... and rodents. , The tissue is metabolically active and the ...
... 8 /PRNewswire-FirstCall/ - IMRIS Inc. (TSX: IM) ("IMRIS" or ... intra-operative MR held at PLA 301 Hospital in Beijing ... USA, Germany, Taiwan and Hong Kong attended the inaugural ... neurosurgery. The conference was opened by Dir Chen Xiaohong, ...
... Michael Eskew Named New Chair of Audit CommitteeINDIANAPOLIS, April 8 ... (NYSE: LLY ) today announced that J. Michael ... 2009. Mr. Cook, the retired chairman and chief executive officer ... the Lilly board since 2005. Mr. Cook has been a ...
... Serve Health Professionals, Instructors and Counselors , ... Today the American Psychological Association (APA) notified Humanitas, ... stringent criteria to offer continuing education credit hours ... programs. Humanitas offers a variety of educational ...
... Researchers and Updates on Key Discoveries, Plus Panel ... 8 Internationally renowned physician-scientists will discuss the ... plus important recent discoveries in translational cancer research, ... Research Foundation Clinical Investigator Symposium.The April ...
... 8 ORLANDO, Fla., April 8 James ... opening of his new dental practice, DellagioDentist.com, ... Orlando. This new dental practice, located at ... 8.(Photo: http://www.newscom.com/cgi-bin/prnh/20090408/CG96485 )Dr. Trantham and ...
Cached Medicine News:Health News:A Fat That May Keep You Thin 2Health News:A Fat That May Keep You Thin 3Health News:Neurosurgeons from around the world gather at PLA 301 Hospital in China 2Health News:J. Michael Cook to Retire from Lilly Board of Directors 2Health News:Humanitas Approved by American Psychological Association (APA) as Provider of Continuing Education Credits to Psychologists 2Health News:Humanitas Approved by American Psychological Association (APA) as Provider of Continuing Education Credits to Psychologists 3Health News:Top Physician-Scientists Discuss State of Cancer Research at Damon Runyon Cancer Research Foundation Symposium 2Health News:Top Physician-Scientists Discuss State of Cancer Research at Damon Runyon Cancer Research Foundation Symposium 3Health News:Top Physician-Scientists Discuss State of Cancer Research at Damon Runyon Cancer Research Foundation Symposium 4Health News:New Family Dental Practice Opens in Orlando 2
(Date:7/31/2015)... 2015  Semler Scientific, Inc. (Nasdaq: SMLR ), ... healthcare insurers and physician groups, today reported financial results ... "In the second quarter of 2015, Semler ... of 54%, quarter over quarter revenue growth of 8%, ... of FloChec® units of 18%," said Doug Murphy-Chutorian, M.D., ...
(Date:7/30/2015)... , July 30, 2015 Edwards Lifesciences Corporation (NYSE: ... heart valves and hemodynamic monitoring, today announced that Robert ... Directors. "Bob is an ardent champion for innovation ... privilege to have him on Edwards, board as we pursue ... Edwards, chairman and CEO.  "Bob has provided a valuable perspective ...
(Date:7/30/2015)... 30, 2015  Tandem Diabetes Care®, Inc. (NASDAQ: ... manufacturer of the t:slim® and t:flex™ Insulin Pumps, ... Development Agreements with Dexcom, Inc. to allow the ... the Dexcom G5 and G6 continuous glucose monitoring ... pump platform with Dexcom,s future CGM systems is ...
Breaking Medicine Technology:Semler Reports Second Quarter 2015 Financial Results 2Semler Reports Second Quarter 2015 Financial Results 3Semler Reports Second Quarter 2015 Financial Results 4Semler Reports Second Quarter 2015 Financial Results 5Semler Reports Second Quarter 2015 Financial Results 6Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 2Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 3
... N.Y., June 30 XTL,Biopharmaceuticals Ltd. (Nasdaq: XTLB ... randomization into its Phase 2b study of Bicifadine,-- a ... of diabetic neuropathic pain. 350 patients were randomized into,the ... expects to,have the last patient complete the study in ...
... Co (NYSE:,LLY) and Boehringer Ingelheim today announced that ... of the European Medicines Agency,(EMEA) has issued a ... for the treatment of Generalised Anxiety,Disorder (GAD)., ... of five clinical studies,-- four double-blind placebo-controlled studies ...
Cached Medicine Technology:XTL Biopharmaceuticals Announces Completion of Patient Randomization Into the Bicifadine Phase 2b Clinical Trial for the Treatment of Diabetic Neuropathic Pain 2XTL Biopharmaceuticals Announces Completion of Patient Randomization Into the Bicifadine Phase 2b Clinical Trial for the Treatment of Diabetic Neuropathic Pain 3European CHMP Issues Positive Opinion on Cymbalta for the Treatment of Generalised Anxiety Disorder 2European CHMP Issues Positive Opinion on Cymbalta for the Treatment of Generalised Anxiety Disorder 3European CHMP Issues Positive Opinion on Cymbalta for the Treatment of Generalised Anxiety Disorder 4European CHMP Issues Positive Opinion on Cymbalta for the Treatment of Generalised Anxiety Disorder 5European CHMP Issues Positive Opinion on Cymbalta for the Treatment of Generalised Anxiety Disorder 6
... display of corneal layers: endothelium, ... epithelial layers. Accurate analysis of ... keratocytes, nerve fibres, basal & ... surgery and pathology: optical pachymetry, ...
Ahmed Glaucoma Valve (small size)....
... Long-term biocompatibility is established. Provides a robust ... ensure correct positioning on the globe. Pressure ... which, when covered by Tenons tissue, acts ... postoperative hypotony. The range of implants allows ...
... Goldmann standard automatic or manual ... with white/white, blue/yellow or red/white stimuli/background ... or classic 4-2 threshold strategy. Examination ... grids (including 30-2, 24-2, and 10-2). ...
Medicine Products: